Despite losing a potentially lucrative FLT3 inhibitor partnership with Astellas Pharma Inc

The product is marketed by Genentech Inc., a member of the Basel, Switzerland-based Roche Group, and Astellas Pharma Inc., of Tokyo

ARMOR2, the second study in Tokai's ARMOR (Androgen Receptor Modulation Optimized for Response) program, is testing a new oral formulation of galeterone in CRPC patients, including those with either metastatic or nonmetastatic disease and those whose disease has progressed while on currently approved prostate cancer drugs Zytiga (abiraterone acetate, Johnson & Johnson) or Xtandi (enzalutamide, Medivation Inc. and Astellas Pharma Inc.) Primary endpoints are measuring a reduction in prostate

Astellas Pharma Inc

ErbB1, better known as epidermal growth factor receptor, or EGFR, is the target of drugs such as Tarceva (erlotinib, Roche AG and Astellas Pharma Inc.), Iressa (gefitinib, AstraZeneca plc.), Vectibix (panitumumab, Amgen Inc.) and Erbitux (cetuximab, Eli Lilly and Co.) Roche drugs Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) target ErbB2, which also goes by HER2/neu

once-daily Multiple sclerosis Was approved in Argentina in a 14 mg formulation for patients with relapsing forms 4/9/13 CANCER Celgene Corp. (Summit, N.J.) Revlimid Lenalidomide Transfusion-dependent anemia CHMP adopted a positive opinion for Revlimid 4/29/13 Curis Inc. (Lexington, Mass.) Erivedge Vismodegib Symptomatic metastatic basal cell carcinoma CHMP recommended conditional approval 4/29/13 Medivation Inc. (San Francisco) and Astellas Pharma Inc. (Tokyo) Xtandi Enzalutamide Metastatic

Astellas Pharma Inc., of Tokyo, and Drais Pharmaceuticals Inc., of Bridgewater, N.J., will repeat for the third time a spinout maneuver that has been successful with two other programs in the past

Tokyo-based Astellas Pharma Inc

In a call after the meeting, AVEO President and CEO Tuan Ha-Ngoc defended the trial AVEO conducted in partnership with Astellas Pharma Inc., of Tokyo, saying the study design was based on consultations with leading experts in the field

Active Biotech AB, of Lund, Sweden, and Ipsen SA, of Paris, said they now plan to conduct the primary progression-free survival analysis for the 10TASQ10 global Phase III trial of tasquinimod in 2014, at the same time as the first interim overall survival analysis, when more mature data are available. The product, a small molecule that binds to S100A9, is the subject of a study across 37 countries in 1,245 metastatic castrate-resistant prostate cancer patients who have not yet received

The data showed strong progression-free survival (PFS), but overall survival (OS) data were less compelling. (See BioWorld Today, Feb. 14, 2013.) Conducted in partnership with Astellas Pharma Inc., of Tokyo, the global, randomized trial enrolled 517 subjects with advanced RCC

For Europe, Ironwood is partnered with Almirall SA in a deal worth up to $95 million, and Astellas Pharma Inc

Almac Discovery, a Craigavon, Northern Ireland-based member of Almac Group Ltd., licensed its anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Co. Ltd., of Seoul, South Korea, for clinical development and marketing in South Korea. Shin Poong will make undisclosed up-front and milestone payments, along with royalties. The South Korean development program will run parallel with Almac's development program in Europe, where the cancer compound is entering Phase I/II trials in the UK

For Europe, Ironwood is partnered with Almirall SA in a deal worth up to $95 million, and Astellas Pharma Inc

Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, said the European Committee for Medicinal Products for Human Use recommended approval of Xtandi (enzalutamide) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy

Stephen Eck, vice present and global head of oncology medical sciences at Astellas Pharma Inc., told BioWorld Today, adding that "the companion diagnostic is a key ingredient of our R&D plans

Revenues of $0.5 million were drawn primarily from a $10 million milestone payment from Tokyo-based Astellas Pharma Inc

it will get an up-front payment, product supply income and be eligible for additional milestone payments 2/21/13 MARCH Astellas Pharma Inc. (Tokyo) Nagasaki University ND Collaborative research agreement to discover new drugs for the treatment of neglected tropical diseases caused by dengue virus Under the terms, the institute of Tropical Medicine at Nagasaki University will cooperate with Astellas on a drug discovery research project, with Astellas providing multiple compounds with possible

Astellas Pharma Inc